View Older Stories View More Recent Stories
-
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing - Bloomberg
-
Novo Nordisk (NVO) gains after oral amycretin presentation
-
Lilly (LLY): Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
-
Piper Sandler answers: who has the best obesity drug of all?
-
Eli Lilly & Co. (LLY) Appoints Lucas Montarce as CFO
-
TD Cowen Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) reports positive topline results from the QWINT-1 and QWINT-3 phase 3 trials
-
Eli Lilly & Co. (LLY) reports positive topline results from the QWINT-1 and QWINT-3 phase 3 trials
-
HAYA Therapeutics Announces Collaboration with Lilly (LLY) to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
-
Eli Lilly & Co. (LLY) and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
-
Truist Defending Viking Therapeutics (VKTX): 'recommend investors take advantage of today’s selloff to add to shares'
-
Deutsche Bank on Eli Lilly (LLY): 'Zep Going (Lilly) Direct to Vials Helps Bridge GLP-1 Supply/Demand'
-
Eli Lilly & Co. (LLY) call put ratio 2.9 calls to 1 put after launches single-dose vials of Zepbound
-
BMO Capital on Eli Lilly (LLY): 'Positive read through to shares with the company taking a meaningful step to improve access for patients'
-
Citi on Hims and Hers (HIMS) Post Lilly (LLY) News: 'Single-dose Zepbound Vials a Shot Across the Bow for the Compounders'
-
Morgan Stanley on Eli Lilly (LLY): 'the incremental volume from vials could prove to be a positive offset'
-
Evercore ISI on Eli Lilly (LLY): 'Bottom-line: estimates not going down...net price may even improve actually!'
-
Eli Lilly & Co. (LLY) releases Zepbound® (tirzepatide) single-dose vials, priced at 50% discount or greater
-
Selloff in MedTech stocks 'seems overdone': Citi
-
Eli Lilly & Co. (LLY) August 13 weekly 890, 895 and 920 calls active as share price up 2.5%
-
Eli Lilly (LLY) is a new large-cap pharma top pick at Wells Fargo
-
Midday movers: Lilly, Palo Alto and Fabrinet rise; Lowe's, Boeing fall
-
Lilly’s Zepbound cuts risk of diabetes by 94% in obese patients, shares gain
-
Organon (OGN) and Lilly (LLY) Expand Migraine Commercialization Agreement to 11 Additional Markets
-
Eli Lilly (LLY): Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
-
Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY), New Large-Cap Pharma Top Pick
-
Eli Lilly & Co. (LLY) Announces Resignation of Marschall S. Runge from Board
-
Lilly (LLY) Completes Acquisition of Morphic
-
Eli Lilly & Co. (LLY) opens state-of-the-art research and development center in the Boston Seaport
-
Deutsche Bank upgrades Eli Lilly stock to Buy, sees 15% upside potential
-
Deutsche Bank Upgrades Eli Lilly (LLY) to Buy
-
Midday movers: Expedia, Lilly rise; Array, Elf Beauty fall
-
Popular stocks with increasing volume: INTC BAC LUV AVGO U MU TSM LLY SMCI
-
Eli Lilly (LLY) PT Raised to $1,101 at BMO Capital
-
Eli Lilly (LLY) PT Raised to $1,150 at BofA Securities
-
Eli Lilly & Co. (LLY) August 900 calls active
-
Midday movers: Eli Lilly, Robinhood and Zillow rise; Warner Bros, Fastly, Bumble fall
-
Eli Lilly stock jumps 10% on annual guidance hike, strong Q2 top and bottom line
-
Eli Lilly & Co. (LLY) Tops Q2 EPS by $1.17, Beats on Revenue; Offers Upbeat FY24 Guidance
-
Eli Lilly & Co. (LLY) August 9 weekly 772.50 straddle into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 2.3 calls to put into quarter results
-
Eli Lilly & Co. (LLY) August 9 weekly 792.50 straddle priced into quarter results
-
Eli Lilly (LLY) PT Raised to $1,050 at Jefferies
-
Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall
-
Eli Lilly stock gains on new weight-loss drug study results, Novo Nordisk down
-
Eli Lilly & Co. (LLY) reports tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
-
Roche to accelerate weight loss drugs development after positive trials - report
-
Early GLP-1 winners Lilly, Novo fall on cautious updates from rival Roche
-
UBS: GLP-1 obesity market to reach $90bn by 2029
-
Shares of this mega-cap pharma stock could outperform soon: Goldman Sachs
